Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 12 (Search time: 0.007 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2012Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLarson, R.; Hochhaus, A.; Hughes, T.; Clark, R.; Etienne, G.; Kim, D.; Flinn, I.; Kurokawa, M.; Moiraghi, B.; Yu, R.; Blakesley, R.; Gallagher, N.; Saglio, G.; Kantarjian, H.
2012Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibWhite, D.; Radich, J.; Soverini, S.; Saunders, V.; Frede, A.; Dang, P.; Cilloni, D.; Lin, P.; Mongay, L.; Woodman, R.; Manley, P.; Slader, C.; Kim, D.; Pane, F.; Martinelli, G.; Saglio, G.; Hughes, T.
2012Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemiaYin, O.; Giles, F.; Baccarani, M.; le Coutre, P.; Chiparus, O.; Gallagher, N.; Saglio, G.; Hughes, T.; Hochhaus, A.; Kantarjian, H.; Larson, R.
2012Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phaseLarson, R.; Yin, O.; Hochhaus, A.; Saglio, G.; Clark, R.; Nakamae, H.; Gallagher, N.; Demirhan, E.; Hughes, T.; Kantarjian, H.; le Coutre, P.
2012Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitorsNieborowska-Skorska, M.; Kopinski, P.; Ray, R.; Hoser, G.; Ngaba, D.; Flis, S.; Cramer, K.; Reddy, M.; Koptyra, M.; Penserga, T.; Glodkowska-Mrowka, E.; Bolton, E.; Holyoake, T.; Eaves, C.; Cerny-Reiterer, S.; Valent, P.; Hochhaus, A.; Hughes, T.; Van der Kuip, H.; Sattler, M.; et al.
2012Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialGuilhot, F.; Hughes, T.; Cortes, J.; Druker, B.; Baccarani, M.; Gathmann, I.; Hayes, M.; Granvil, C.; Wang, Y.
2012BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and managementBranford, S.; Yeung, D.; Prime, J.; Choi, S.; Bang, J.; Park, J.; Kim, D.; Ross, D.; Hughes, T.
2012Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib responseWhite, D.; Hughes, T.
2012Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cellsWang, J.; Hughes, T.; Kok, C.; Saunders, V.; Frede, A.; Groot Obbink, K.; Osborn, M.; Somogyi, A.; D'Andrea, R.; White, D.
2012Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine ABlake, S.; Hughes, T.; Lyons, A.